Health Canada Santé Canada





## FDA – Health Canada ICH Public Meeting

May 14, 2021

## Agenda

- Welcome and Opening Remarks
- Overview of ICH
- Topics Recently Reaching ICH Milestones
- E6 Principles
- Q12 Implementation
- Model Informed Drug Development
- Patient Focused Drug Development
- Q&A/Comment Period



## FDA and Health Canada Regional ICH Consultation Opening Remarks

May 14, 2021

#### Theresa M Mullin, PhD

Associate Director for Strategic Initiatives FDA Center for Drug Evaluation and Research

# Our regional meeting supports the original aims of 2015 ICH Reforms



## Goals for ICH Reform in 2015

- 1. Focus global pharmaceutical regulatory harmonisation work in **one venue**.
- 2. Create a venue that gives to all key pharmaceutical regulatory authorities and industry stakeholders the **opportunity to be more actively involved** in pharmaceutical harmonisation work.
- **3. Maintain efficient and well-managed operations** and harmonisation work processes.

The ICH Association, established in October 2015, is a non-profit legal entity under Swiss law with the aim to focus global pharmaceutical regulatory harmonisation work in one venue. <u>http://www.ich.org/about/articles-procedures.html</u>

# Regional Meetings provide another opportunity for ICH and stakeholder engagement

- Since ICH reforms:
  - Growing participation of regulators and industry in work to harmonize scientific and technical standards for human drugs
  - Increasing recognition of need for external stakeholder engagement and consultation
  - Expanding opportunities for public input via EWG **workshops**, **publication of Reflection Papers** for public comment (e.g., GCP Renovation paper)

FDA

## Significant Global Growth in the Number and Diversity of ICH Participants

### **ICH Members & Observers**

#### **MEMBERS**

#### Founding Regulatory Members

EC, Europe FDA, United States MHLW/PMDA, Japan

### Founding Industry Members

EFPIA JPMA PhRMA

#### Standing Regulatory Members

Health Canada, Canada Swissmedic, Switzerland MEMBERS (continued) Regulatory Members ANVISA, Brazil HSA, Singapore MFDS, Republic of Korea NMPA, China TFDA, Chinese Taipei TITCK, Turkey

#### **Industry Members**

Global Self-Care Federation IGBA BIO

#### OBSERVERS Standing Observers IFPMA WHO

OBSERVERS (continued) Legislative or Administrative Authorities

> ANMAT, Argentina CDSCO, India CECMED, Cuba **COFEPRIS**, Mexico CPED, Israel **INVIMA**, Colombia JFDA. Jordan MMDA, Moldova MOPH, Lebanon National Center. Kazakhstan NPRA, Malaysia NRA, Iran Roszdravnadzor, Russia SAHPRA, South Africa SCDMTE, Armenia SFDA, Saudi Arabia TGA, Australia

**OBSERVERS** (continued) **Regional Harmonisation Initiatives (RHIs)** APEC ASEAN EAC GHC PANDRH SADC International Pharmaceutical **Industry Organisation** APIC **International Organisation** regulated or affected by ICH Guideline(s) Bill & Melinda Gates Foundation CIOMS EDQM IPEC PIC/S

USP





## Approach to promoting ICH standards globally

- Guideline Relevance
  - Focus harmonized guideline work on topics directly relevant to the quality and efficiency of drug development, regulatory review, manufacturing, post-approval oversight
- Scientific Rigor
  - Focus on data-driven consensus-based scientific standards, with work processes that are inclusive and transparent
- Implementation
  - Support through training and continued monitoring progress and challenges in implementation

## FDA and Health Canada Regional ICH Consultation --Presentations

- Overview of ICH
  - Jill Adleberg, FDA
- Guidelines Recently Reaching ICH Milestones (S1 and Q3C)
  - Alisa Vespa, Health Canada
- Guideline Work On-going: ICH E6 GCP Principles
  - Khair ElZarrad, FDA
- Guidelines in Implementation: ICH Q12
  - Ashley B. Boam, FDA
- ICH Discussion Groups: Model Informed Drug Development
  - Scott Marshall, PhRMA (Pfizer)
- ICH Reflection Papers: Patient Focused Drug Development
  - Robyn Bent, FDA
- Q&A/Comment Period

FDA



## Thank you



## **ICH Overview**

### **Jill Adleberg**

### ICH Coordinator International Programs, Office of the Center Director CDER | US FDA

FDA/HC ICH Regional Public Meeting – May 14, 2021

## **ICH** Overview



- The International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) is a unique harmonization organisation involving regulators <u>and</u> the pharmaceutical industry.
- Launched in 1990 by the US, EU, and Japan. Canada, Swissmedic and WHO as observers.
- Well-defined objectives:
  - To improve efficiency of new drug development and registration processes
  - To promote public health, prevent duplication of clinical trials in humans and minimize the use of animal testing without compromising safety and effectiveness
- Accomplished through development of harmonized, technical guidelines and standards that are implemented by regulatory authorities.

## **ICH** Association



Reformed as a non-profit legal entity under Swiss Law in 2015 to promote public health through international harmonization that contributes to:

- Focus global pharmaceutical regulatory harmonization work in a single forum for constructive dialogue on scientific issues
- Promote more involvement from regulators around the world and wider inclusion of global industry sectors
- Continue to harmonize and streamline the global drug development process for the benefit of patients around the world
- Facilitate greater adoption of new and improved research and development approaches, common standards, and therapeutic advances
- Maintain efficient and well-managed operations

## **ICH Members and Observers**

#### **Founding Regulatory Members**

- EC, Europe
- FDA, US
- MHLW/PMDA, Japan

#### **Founding Industry Members**

- EFPIA
- PhRMA
- JPMA

#### **Standing Observers**

- IFPMA
- WHO

#### Legislative or Administrative Authorities

- ANMAT, Argentina
- CDSCO, India
- CECMED, Cuba
- COFEPRIS, Mexico
- CPED, Israel
- INVIMA, Colombia
- JFDA, Jordan
- MMDA, Moldova
- MOPH, Lebanon

#### Members

#### **Standing Regulatory Members**

- Health Canada, Canada
- Swissmedic, Switzerland

#### **Regulatory Members**

- ANVISA, Brazil
- HSA, Singapore
- MFDS, Republic of Korea

#### Observers

- National Ctr, Kazakhstan
- NPRA, Malaysia
- NRA, Iran
- Roszdravnadzor, Russia
- SAHPRA, South Africa
- SCDMTE, Armenia
- SFDA, Saudi Arabia
- TGA, Australia

#### **Regional Harmonization Initiatives**

- APEC
- ASEAN
- EAC

- NMPA, China
- TITCK, Turkey
- TFDA, Chinese Taipei

#### **Industry Members**

- BIO
- Global Self-Care Federation
- IGBA

- GHC
- PANDRH
- SADC

#### Int'l Pharmaceutical Industry Organizations

APIC

#### Int'l Orgs regulated by or affected by ICH guidelines

- Bill & Melinda Gates Foundation
- CIOMS
- EDQM
- IPEC
- PIC/S
- USP

## FDA

## **ICH Products**



- ~70 guidelines on technical requirements related to human drugs
- Electronic Standards for the Transfer of Regulatory Information (CTD/eCTD, ICSRs)
- Medical Dictionary for Regulatory Activities (MedDRA) -- standardized medical terminology to facilitate regulatory information sharing

## Major ICH Topic Areas




	Safety	
	Carcinogenicity studies Genotoxicity studies Toxicokinetics and Pharmacokinetics Duration of chronic toxicity testing Reproductive toxicology	<ul> <li>Safety pharmacology studies</li> <li>Immunotoxicology studies</li> <li>Nonclinical evaluation for anticancer pharmaceuticals</li> <li>Photosafety evaluation</li> <li>Nonclinical pediatric safety</li> </ul>
Efficacy		
	Clinical safety Clinical study reports Dose-response studies Good clinical practice	<ul> <li>Clinical trials</li> <li>Clinical evaluation by therapeutic category</li> <li>Clinical evaluation</li> <li>Pharmacogenomics</li> </ul>
	Quality	
	Stability Analytical validation Impurities Pharmacopoeias Specifications	<ul> <li>Good manufacturing practice</li> <li>Pharmaceutical development</li> <li>Quality risk management</li> <li>Pharmaceutical quality system</li> <li>Development and manufacture of drug substances</li> </ul>
Multidisciplinary		
vw.fda.gov	MedDRA terminology Electronic standards Nonclinical safety studies CTD and eCTD Bioanalytical Method Validation Biopharmaceutics Classification System-based Biowaivers	<ul> <li>Data elements and standards for drug dictionaries</li> <li>Gene therapy</li> <li>Mutagenic impurities</li> <li>Drug Interaction Studies</li> <li>Bioequivalence for IR solid</li> </ul>

## Composition of ICH Working Groups



Over 700 experts in 34 working groups



www.fda.gov

### FDA ICH Guideline Development **5 Step Process STEP 5 STEP 4** Resulatory nation **STEP 3** Final Guideline **STEP 2** 3 Approved Public Insultation **STEP 1** Draft Guideline Approved consensus Building

## **ICH Training**



### **Guideline Training:**

• ICH is working to ensure that high quality training is available based upon scientific and regulatory principles outlined in its guidelines.

### **Efforts include:**

- Development of a Training Library on the ICH website with access to all training materials including Step 4 working group presentations.
- Funding support for training programs organized by ICH regulatory members and observers.
- ICH Recognized Training Programs hosted by a variety of organizations, associations, regulatory authorities and academia. Offered in-person, virtually, and online. Information available on the ICH website.
- Online training materials development including some translations.

## **ICH Governance**


## FDA

### Assembly

• The overarching body, comprised of all ICH Members and Observers, that makes decisions regarding the Articles of Association and its rules and procedures, admission of new members, election of Management Committee representatives, adoption of ICH guidelines, etc.

### **Management Committee**

- Oversees operational aspects on behalf of all members of the Association, including <u>administrative and financial matters</u> and oversight of WG operations.
- Financial responsibilities include preparation of the ICH budget and, during a transition period, ensure funding of ICH operations.
- Includes Permanent and Standing Members, and Elected Members



#### www.fda.gov



## Eligibility Criteria: <u>Regulators</u>

### **Recognized Authority**

- Has a legal personality
- Responsible for regulation of pharmaceuticals for human use

### **Engagement in the ICH Process**

- Past regular attendance in at least 3 ICH meetings during the previous 2 consecutive years
- Past appointment of experts in at least 2 working groups

### **Application of ICH Guidelines**

At minimum, implemented the following guidelines:

- Q1: Stability Testing
- Q7: Good Manufacturing Practices for Active Pharmaceutical Ingredients
- E6: Good Clinical Practice

## Eligibility Criteria: Industry

### **Recognized Authority**

- Has a legal personality
- Represents members from several countries in at least three continents
- Organization or its members regulated by ICH guidelines

### **Engagement in the ICH Process**

- Has participated in ICH as an observer
- Past regular attendance in ICH meetings
- Past appointment of experts in 2+ working groups

## Summary



### ICH:

- Draws on expertise of regulators and industry to achieve international harmonization of technical guidelines to enhance public health
- Uses a transparent, science- and consensus-based process for guideline development including opportunities for public comment
- Includes commitment of regulators to implement guidelines
- Has expanded global participation and engagement through recent reforms



## Topics Recently Reaching Step 3 or 4 of the ICH Process: ICH Q3C(R8) & Addendum to ICH S1B(R1)

## 14 May 2021

**Alisa Vespa, Ph.D.** Office of Risk Management Bureau of Medical Sciences Therapeutic Products Directorate, Health Canada

YOUR HEALTH AND SAFETY ... OUR PRIORITY.

- Q3C(R8): Impurities: Guideline for Residual Solvents
  - Permitted daily exposures (PDEs) for 3 new solvents
- S1B(R1): Testing for Carcinogenicity of Pharmaceuticals
  - Addendum to S1B
  - Expands the testing scheme for assessing human carcinogenic risk of small molecule pharmaceuticals

## ICH Q3C(R8): Guideline for residual solvents

PDEs for 2-methyltetrahydrofuran, cyclopentyl methyl ether, and tertiary-butyl alcohol

## ICH Q3C(R8): Guideline for residual solvents

Purpose of the ICH Q3C guideline

• To recommend Permitted Daily Exposure (PDE) levels of residual solvents in pharmaceuticals to ensure patient safety

## **Document history**

- ICH Q3C core guideline adopted by ICH in June 1997
- In 1999, maintenance expert working group formed to:
  - Revise existing PDEs as new toxicity data becomes available
  - Develop monographs and derive PDEs for new solvents when adequate toxicity data is available
- ICH Q3C has undergone several revisions over the past 20 years

## Timeline of current update

- Consensus reached in May 2017 to develop monographs and derive PDEs for the following solvents:
  - 2-Methyltetrahydrofuran
  - Cyclopentyl methyl ether
  - Tertiary-butyl alcohol
- Step 1 draft document endorsed by ICH Assembly (March 2020)
- Step 3 regulatory consultation, EWG discussion, document revision (April 2021)
- Step 4 adoption of the guideline by ICH Assembly (April 2021)

https://database.ich.org/sites/default/files/ICH\_Q3C-R8\_Guideline\_Step4\_2021\_0422\_1.pdf

## ICH Q3C(R8): Guideline for residual solvents

## 2-Methyltetrahydrofuran (2-MTHF): Summary of toxicity data

- Genotoxicity
  - No evidence of genotoxic potential
- Carcinogenicity
  - No data available
- Reproductive toxicity
  - No reliable studies for PDE calculation
- Repeat dose toxicity
  - Two 3-month oral rat studies available
  - One of the studies was appropriate calculating PDE

2-Methyltetrahydrofuran (2-MTHF): Derivation of PDE

- Male and female rats orally dosed with 2-MTHF at 80, 250, 500 and 1000 mg/kg/day for 3-months
- NOEL = 250 mg/kg/day

 $PDE = \frac{250 \text{ mg/kg/day x 50 kg (weight adjustment)}}{5 \text{ x 10 x 5 x 1 x 1 (modifying factors)}} = 50 \text{ mg/day}$ 

Outcome of regulatory consultation

- Monograph updated to include results of an OECD 414 & GLPcompliant rat developmental toxicity study
- No change to PDE

- 2-Methyltetrahydrofuran (2-MTHF)
- PDE = 50 mg/day
- Placed into Class 3 "solvents with low toxic potential"

## ICH Q3C(R8): Guideline for residual solvents

## Cyclopentyl methyl ether (CPME): Summary of toxicity data

- Genotoxicity
  - No evidence of genotoxic potential
- Carcinogenicity
  - No data available
- Reproductive toxicity
  - No reliable studies for PDE calculation
- Repeat dose toxicity studies in rats
  - Two oral (28-day, 90-day) and one 90-day inhalation study
  - NOEL from 28-day oral study considered most appropriate for PDE calculation

Cyclopentyl methyl ether (CPME): Derivation of PDE

- Male and female rats orally dosed with CPME at 15, 150 and 700 mg/kg/day for 28 days
- NOEL = 150 mg/kg/day

PDE = 150 mg/kg/day x 50 kg (weight adjustment) = 15 mg/day5 x 10 x 10 x 1 x 1 (modifying factors)

## ICH Q3C(R8): Guideline for residual solvents

Outcome of regulatory consultation

- Minor editorial revisions made to the monograph
- No change to PDE

Cyclopentyl methyl ether (CPME)

- PDE = 15 mg/day
- Placed into Class 2 "solvents to be limited"

## ICH Q3C(R8): Guideline for residual solvents

Tertiary-butyl alcohol (TBA): Summary of toxicity data

- Genotoxicity
  - No evidence of genotoxic potential
- Reproductive and developmental toxicity

  - NOAEL = 400 mg/kg/day

## ICH Q3C(R8): Guideline for residual solvents

## Tertiary-butyl alcohol (TBA): Summary of toxicity data

• Repeat dose toxicity: Two 13-week drinking water studies

Rats:

- Mortality at high dose
- Adverse effects in the kidney (nephropathy) and urinary bladder (inflammation) in both sexes
- LOEL = 176 mg/kg/day

### Mice:

- Mortality at high dose
- Adverse effects in the urinary bladder (hyperplasia/inflammation) in both sexes
- NOEL = 1786 mg/kg/day

Tertiary-butyl alcohol (TBA): Summary of toxicity data

- Carcinogenicity: Rat and mouse drinking water studies (NTP)
  - Primary targets of toxicity and carcinogenicity were the kidney in rats; thyroid gland and urinary bladder in mice
  - NTP conclusion: "some evidence of carcinogenic activity" in male rats and female mice
- The 2-year carcinogenicity studies were considered the most appropriate to support calculation of the PDE
- A PDE was calculated for each carcinogenicity study



Tertiary-butyl alcohol (TBA): Derivation of PDE

- Rats orally dosed with TBA at 85, 195 and 420 mg/kg/day (males) and 175, 330, 650 mg/kg/day (females)
- LOEL = 175 mg/kg/day based on nephropathy in females

 $PDE = \frac{175 \text{ mg/kg/day x 50 kg (weight adjustment)}}{5 \text{ x 10 x 1 x 1 x 5 (modifying factors)}} = 35 \text{ mg/day}$ 

### ICH Q3C(R8): Guideline for residual solvents

Outcome of regulatory consultation

- Minor editorial revisions made to the monograph
- No change to PDE

Tertiary-butyl alcohol (TBA)

- PDE = 35 mg/day
- Placed into Class 2 "solvents to be limited"

### ICH S1B(R1): Addendum to the Guideline on Testing for Carcinogenicity of Pharmaceuticals

### Purpose of the ICH S1B guideline

 Provides guidance on approaches for evaluating the carcinogenic potential of pharmaceuticals

Document history

• ICH S1B guideline adopted by ICH in July 1997

## ICH S1B(R1): Carcinogenicity Testing - Addendum

Current options for carcinogenicity testing

Option 1

- 2-year study in one rodent species (e.g., rat)
- Short- or medium-term *in vivo* rodent study (e.g., RasH2-Tg)

Option 2

- 2-year study in one rodent species (rat)
- 2-year study in 2<sup>nd</sup> rodent species (mouse)

#### Work process and timeline

- Concept paper and business plan developed (November 2012)
- Prospective evaluation study launched (August 2013)
  - Regulatory Notice document (RND) posted on ICH website
  - Several status reports posted on ICH website
- EWG consensus on Step 1 draft Addendum reached (March 2021)
- Step 1 draft Addendum endorsed by ICH Assembly (April 2021)
- Step 3 regulatory consultation to be initiated shortly


#### Purpose of the Addendum


- Expands testing scheme for assessing human carcinogenic risk of small molecule pharmaceuticals
  - Weight-of-evidence (WoE) approach to determine if a 2-year rat study adds value
  - Does not replace existing S1B guideline
- Includes a plasma exposure ratio endpoint for high dose selection in rasH2-Tg mouse model

#### ICH S1B(R1): Carcinogenicity Testing - Addendum

Possible conclusions following WoE assessment

- Likely to be carcinogenic in humans
- Likely not to be carcinogenic in humans
- Carcinogenic potential in humans uncertain





#### Factors to consider for WoE assessment

- Drug target biology & primary pharmacologic mechanism
   Carcinogenicity data for compounds in drug class
- Off-target potential (e.g., secondary pharmacology screens)
- Histopathology data from repeat-dose toxicity studies
  - Long-term rat study most informative
  - Include exposure margin assessment
- Evidence of hormonal perturbation
- Genetic toxicology data (ICH S2(R1))
- Evidence of immune modulation (ICH S8)

24

### ICH S1B(R1): Carcinogenicity Testing - Addendum

If WoE factor(s) are inconclusive or indicate a concern

- Additional investigations may be needed to inform human relevance of potential risk:
  - Conduct additional investigational studies
  - Analyze specimens collected from prior studies
  - Clinical data to inform human mechanistic relevance at therapeutic exposures

### Integration of WoE factors

- Integrated analysis determines whether or not 2-year rat study will add value to the assessment of human carcinogenic risk
  - Case studies in Appendix 1
- Novel drug targets (i.e., first-in-class) eligible for a WoE approach
  - Higher evidentiary standard to demonstrate no cause-forconcern

Mouse carcinogenicity studies

- Remains recommended component of carcinogenicity testing plan
- Exception in the EU:
  - When WoE assessment indicates a 2-year rat study does not add value, a mouse carcinogenicity study is not recommended

High dose selection for RasH2-Tg carcinogenicity studies

- 25-fold plasma AUC exposure ratio (rodent:human) can be used for high dose selection in 2-year rodent studies [ICH S1C(R2)]
  - Does not apply to 6 month RasH2-Tg study
- Retrospective assessment of RasH2-Tg studies indicates no value in exceeding a 50-fold plasma AUC exposure ratio (rodent:human)
  - Manuscript to be published by Hisada et. al.
  - Does not apply to other transgenic mouse models

## ICH S1B(R1): Carcinogenicity Testing - Addendum

Next steps

- Public consultation in the ICH regions to be initiated
- Comments can be submitted as follows
  - Health Canada: <u>hc.ich.sc@canada.ca</u>
  - US FDA: <u>www.regulations.gov</u> (once Addendum is published in the federal register)
- Discuss comments received in each regulatory region
  - Revise Addendum as appropriate
- Finalization of the Addendum as a Step 4 document planned for summer 2022

- ICH Q3C expert working group
- ICH S1 expert working group

## **Questions?**



## ICH E6(R3) Guideline for Good Clinical Practice An Important Global Standard for Clinical Trial Conduct

M. Khair ElZarrad

Deputy Director -Office of Medical Policy CDER | US FDA

FDA and Health Canada Regional ICH Consultation

May 14, 2021

#### www.fda.gov

## For today...

- Rapidly evolving evidence generation ecosystem
- Description of ICH-E6(R3) Expert Working Group (EWG) approach
  - □ ICH E6(R3) development strategy
  - Analysis of public input
  - **Stakeholder engagement**
- Published draft E6(R3) introduction and principles

Overview of draft introduction

- Overview of draft principles
- Invitation to the EWG web-conferences on May 18 & 19.






## **ICH E6 - Guideline for Good Clinical Practice**

- E6: Good Clinical Practice (GCP) finalized in 1996
- Describes the responsibilities and expectations of stakeholders in the conduct of clinical trials
- E6 covers aspects of monitoring, reporting, and archiving clinical trials
- E6 (R2) finalized in 2016
  - Addendum to encourage implementation of more efficient GCP approaches
  - Updated standards for electronic records

## ICH E6: An Important Global Standard

## **Conceptual Representation of the Approach to ICH E6(R3)**



#### **Approach to E6(R3) Development** Simultaneous work on the principles & Annex-1 Step-4 Endorsement of Concept Paper – Nov - 2019 Simultaneous work streams Principles + Annex 1 in Step-3 Principles Feedback **Close coordination** Annex-2 Annex –1 **Develop Updated Concept** Annex 2 reaching Publishing draft, Paper for Annex 2 Step-1 work-in-progress, intro & principles Approximately 24 months

Approximately 12-18 months

www.fda.gov



E6(R3) development is informed by the results of an extensive analysis of stakeholder input and by consistent engagement with stakeholders.

## E6(R3) Expert Working Group (EWG) Analysis



- Analysis is comprised of two approaches:
  - An analysis of stakeholder comments on E6(R2)
  - An analysis of select ICH guidelines to help align between relevant guidelines whenever appropriate
- Goals of this analysis
  - Identify opportunities for improvement in E6(R3) and provide the EWG with potential options on how and where to apply the modifications

## Sample of Resources Used to Inform the Analysis



## **Stakeholder Comment Analysis**

- Academic feed Responses
  - Open letters & published articles
- CTTI "Informing the Renovations to the ICH E6" Project
  - Stakeholder Survey, In-depth Interviews, Open Comments
- Public Engagement Materials
  - Americas Engagement Meeting
  - Europe Engagement Meeting
  - Japan Engagement Meeting

## ICH Guideline Analysis

- All Efficacy Guidelines + M11
- Peer-review publications

## **Examples of Areas Identified for Potential Updates**

- **Data Management** (e.g., consider digitization of data ecosystems)
- **Responsibilities** (e.g., consider variable roles, clarity of tasks, delegation)
- **Monitoring** (e.g., consider highlighting further the importance of risk-based approaches, variety of monitoring approaches)

## **Engagement is Essential to Inform EWG Work**



- Acknowledging the wide impact of E6 and the many stakeholders who are affected by this guideline, the ICH Management Committee approved an engagement plan\* for the E6(R3) EWG.
- The engagement plan includes:
  - Public engagements, such as conducting web-conferences, and publishing updates. As a part of the EWG continuous transparency and engagement efforts, the EWG published draft, work-in-progress principles and is organizing a webconference for May 18 & 19 (<u>https://www.ctti-clinicaltrials.org/briefing-room/meetings/ich-e6-guidelinegood-clinical-practice-%E2%80%93-update-progress</u>)
  - Direct EWG engagement with academic experts during the EWG meetings as the work on the guideline proceeds

\*ICH E6 Summary Engagement Plan - https://admin.ich.org/sites/default/files/2020-05/E6-R3\_PublicEngagemenSummary\_2020\_0421.pdf


## **EWG Stakeholder Engagement**



Nominated stakeholders that engage directly with the EWG as the work evolves

Organization Name	Representative Name
Society of Clinical Trials (USA)	Pamela Tenaerts, MD
Network of Networks (Canada)	Lisa Johnston, RN
Healthcare Professionals Working Party (EU)	Martin Landray, PhD
Brazilian Society of Clinical Research Professionals (Brazil)	Vivienne Castilho, PharmD
Chinese Pharmaceutical Association (China)	Haiyan Li, MD
The Clinical Research Core Hospital (Japan)	Kenichi Nakamura, MD, PhD

## ICH E6(R3) Introduction and Principles



## ICH E6(R3) Introduction and Principles

Draft E6(R3) Introduction & Principles published in April 2021 Overarching principles that apply across the board

- Comprehensive principles that remain relevant as technology evolves and clinical trial design advances
- Leveraging and facilitating an increasingly digital ecosystem
- Risk-based approach and proportionality
- Thoughtful process throughout clinical trial conception, design, conduct and analyses

# ICH E6(R3) Introduction



- Clinical trials are a fundamental part of clinical research that support the development of new medicines or uses of existing medicines.
- The principles of GCP are designed to be flexible and applicable to a broad range of clinical trials.
- The principles and E6(R3) in general are being developed to encourage thoughtful consideration and planning to address specific and potentially unique aspects of an individual clinical trial.
- The principles are intended to support improved and more efficient approaches to trial design and conduct. For example, innovative digital health technologies may expand the possible approaches to trial conduct. Such technologies can be incorporated in existing healthcare infrastructures and enable the use of a variety of relevant data sources in clinical trials.

# ICH E6(R3) Introduction



- The use of technology in the conduct of clinical trials should be adapted to fit the participant characteristics and the trial design.
- The use of innovative technologies may help enable those designing and conducting a trial to include relevant patient populations.
- The process of building quality into the design of the trial may be supported by participation of those directly involved. These may include a broad range of stakeholders, including patients and treating physicians.
- This guideline is intended to be media neutral to enable the use of different technologies for the purposes of documentation.

# ICH E6(R3) Introduction



- Clinical trials should be designed to protect the rights, safety and well-being of participants and assure the reliability of results.
- Clinical trial designs and processes should be proportionate to the risks inherent in the trial and the importance of the data being collected.
- Trial designs and processes should be evaluated to minimize unnecessary complexity and burden.

# ICH E6(R3) Principles



- The overarching principles provide a flexible framework for clinical trial conduct.
- They are structured to provide guidance throughout the lifecycle of the clinical trial.
- These principles are applicable to trials involving human participants, i.e., healthy volunteers or patients.
- The principles are interdependent and should be considered in their totality to assure ethical trial conduct and reliable results.

# ICH E6(R3) Principles



1. Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with good clinical practice (GCP) and applicable regulatory requirement(s).



2- Clinical trials should be designed and conducted in ways that ensure the rights, safety, and wellbeing of participants.



3- Informed consent is an integral feature of the ethical conduct of a trial. Clinical trial participation should be voluntary and based on a consent process that ensures participants are well-informed.



#### 4- Clinical trials should be subject to objective review by an institutional review board (IRB)/independent ethics committee (IEC).



#### 5- Clinical trials should be scientifically sound for their intended purpose, and based on robust and current scientific knowledge and approaches.



## 6- Clinical trials should be designed and conducted by qualified individuals.



## 7- Quality should be built into the scientific and operational design and conduct of clinical trials.



#### 8- Clinical trial processes, measures, and approaches should be proportionate to the risks to participants and to the reliability of trial results.



## 9- Clinical trials should be described in a clear, concise, and operationally feasible protocol.



#### **10- Clinical trials should generate reliable results.**



# 11- Roles, tasks and responsibilities in clinical trials should be clear and documented appropriately.



12- Investigational products used in a clinical trial should be manufactured in accordance with applicable Good Manufacturing Practice (GMP) standards and be stored, shipped, and handled in accordance with the product specifications and the trial protocol.

#### **Summary**



- Well designed and conducted clinical trials are essential
- The EWG shares the perspective that trials should be efficient and robust to inform the decisions of many stakeholders
- ICH E6(R3) is being developed as a robust and responsive guideline that facilitates innovation while protecting trial participants
- The EWG is actively working on Annex-1 and will continue to focus on a risk-based approach to GCP.
- Please join us for May 18 & 19 web-conferences
   (https://www.ctti-clinicaltrials.org/briefing-room/meetings/ich-e6-guideline-good-clinical-practice-%E2%80%93-update-progress)

#### ICH E6 Expert Working Group (EWG) Members

FDA

**Rapporteur:** Dr. Khair ElZarrad (FDA, United States)

**Regulatory Chair:** Dr. Fergus Sweeney (EC, Europe)

ANVISA, Brazil - Dr. Carla Abrahao Brichesi, Ms. Miriam Onishi

CDSCO, India - Mr. Arun Kumar Pradhan

EC, Europe - Ms. Lisbeth Bregnhøj, Ms. Gabriele Schwarz

EFPIA – Ms. Susanne Nørskov, Ms. Rebecca Stanbrook

FDA, United States - Dr. Celia Witten, Dr. Kassa Ayalew

Health Canada, Canada – Dr. Carole Légaré

HSA, Singapore – Ms. Sumitra Sachidanandan

IFPMA – Mr. Guodong FANG

IGBA – Dr. Gerald Beuerle, Dr. Manjunath Krishnappa

JPMA – Mr. Mitsuaki Aoyagi, Mr. Eiji Kawakatsu

MHLW/PMDA, Japan – Ms. Kanako Ito, Ms. Eriko Yamazaki

NMPA, China – Ms. Zhimin Yang

PhRMA – Ms. Deborah Driscoll

PIC/S – Ms. Gail Francis

Roszdravnadzor, Russia – Mr. Dmitrii Gorenkov

TFDA, Chinese Taipei – Ms. Yi-Ting Chen

TGA, Australia – Dr. Nitin Bagul

TITCK, Turkey – Ms. Nihan Burul Bozkurt

WHO – Dr. Ray Corrin

#### ICH E6(R3) EWG Members



FDA



#### **ICH Q12 Implementation**

#### Ashley B. Boam, MSBE

Director, Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality CDER | US FDA

FDA and Health Canada Regional ICH Consultation – March 14, 2021

#### Overview



- Objectives and scope
- Regulatory tools
- Status of the guideline
- Implementation Working Group activities
- FDA Implementation



#### ICH Q12 – Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management



## ICH Q12 Objectives

- Objectives\* include:
  - ...Harmonize change management...in a more transparent and efficient manner...across ICH regions
  - ...Facilitate risk-based regulatory oversight...
  - Emphasize...control strategy as a key component of the...dossier
  - Support continual improvement and facilitate introduction of innovation
  - Enhance use of regulatory tools for prospective change management...enabling strategic management of post-approval changes...

www.fda.gov



#### Scope

- Pharmaceutical drug substances and products (both chemical and biological) that require a marketing authorization
  - includes innovators, generics, biosimilars
- Drug-device combination products that meet the definition of a pharmaceutical or biological product
  - In the US, this includes CDER- and CBER-led drug-device and biologicdevice combination products
- Does not include changes needed to comply with Pharmacopeial monographs



#### Tools in Q12


- Established Conditions
- Post-approval Change Management Protocols
- Product Lifecycle Management Document
- Structured Approaches for Frequent CMC Post-Approval Changes





#### ICH Q12 Status

#### Step 4 reached in November 2019 (Singapore)



www.fda.gov

RECEL STORY EXPLOY Mina & France II 19 201 Vin Section 11. 13 2019 the without any my





#### Implementation

- Regions are beginning implementation
  - Regulatory Members of ICH are encouraged to provide publicly available information, preferably on their website, about the implementation of ICH Q12 in their region, especially with regard to regulatory considerations
- Formation of the Implementation Working Group (IWG)
  - Concept paper approved in March 2020
  - IWG developing global training materials
  - ICH pilot with PIC/S to develop training materials for inspectorates

### Q12 IWG

FDA

Training materials

- For ICH and non-ICH regions
- Modules addressing each section of guideli
  - Slides for 8 modules to be posted on ICH website
- Case studies with additional examples and narrative text
  - Based on input provided during public consultation period
- Examples include:

PQS

www.fda.gov

ECs for API ECs for vaccine product

Drug-device combination



PACMP

PLCM

ECs for analytical

### Q12 IWG



- Ongoing regional implementation
  - Shared experiences and lessons learned from implementation
  - Both regulators and industry
    - FDA Established Conditions pilot



#### ICH Q12 – FDA Implementation



- FDA adoption and publication
  - Replaces 2015 draft guidance Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products
- Draft guidance on considerations for ICH Q12 implementation awaiting publication
  - Intended to clarify how to implement Q12 within US regulatory system
- CDER MAPP on implementation of ICH Q12 in progress
- Significant training executed (2018-present)
  - Developed and initiated a multi-phase strategy to build awareness and capability within FDA staff



#### FDA – Established Conditions (ECs) Pilot

- FDA initiated a pilot in 2019 to evaluate EC proposals
- Accepted nine applications into the pilot
  - Mixture of small and large molecule, originals and supplements, innovator and generic
- Experience and learnings have informed FDA's ICH Q12 implementation guidance and MAPP





#### ICH Q12 – FDA Training

- Phase 1:
  - Created awareness and clarity on ICH Q12 (goals, content, scope, core elements)
  - Utilized theoretical examples to illustrate concepts and practice the identification of established conditions
- Phase 2:
  - Augmented understanding of pharmaceutical quality systems, CGMP, and their role in ICH Q12 implementation





#### ICH Q12 – FDA Training

- Phase 3:
  - Driven by assessment teams from the established conditions pilot
  - Utilized real world examples to demonstrate implementation
  - Teams shared their experiences assessing proposals and working with applicants
- Phase 4: To be implemented
  - ICH Q12 support team to work with assessors to help answer questions, provide oversight to guide consistency, etc.

#### Summary



- ICH Q12 includes tools and enablers to facilitate innovation and continual improvement
- Implementation is underway at FDA and with other regulators
- ICH Q12 IWG developing training materials to support global implementation



## **Questions?**

#### Ashley B. Boam, MSBE

Director, Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality CDER | US FDA



#### Model Informed Drug Development (MIDD)

#### Scott Marshall, PhD, Executive Director Pfizer R&D UK Ltd & PhRMA MIDD working group on behalf of ICH MIDD Discussion group

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use



## "A world without modelling and simulation would be full of unanswered questions..."



#### **Learning objectives**

- What is Model Informed Drug Development
- Why is it important for efficient drug development
- Why there is a need for global harmonisation in this area
- The remit of ICH MIDD discussion group



- Integration of data from multiple sources
- in the form of mathematical and statistical models

 Application of these models to inform drug development and registration strategies, to optimize the design of future clinical studies & to address dose-individualization questions

#### What is Model Informed Drug Development?

harmonisation for better health

#### Data from multi-sources

Can enrich clinical trial data by utilising non-clinical and Real-World Evidence

#### Mathematical & Statistical Models

Assumptions based on Pharmacology, Physiology & Disease Process



#### Drug development and registration strategies

 Probability of acceptable benefit risk & probability of clinical trial/program success


#### Optimize the design of future clinical studies

• With respect to the range of possible outcomes

#### Address dose-individualization questions

• Optimize for population, sub-population & individual

### H MIDD has Broad Utility Over the Entire Drug Discovery and Development Continuum



EFPIA workgroup CPT:PSP 2016



## MIDD utilization and presentation as part of regulatory Review

### **MIDD: Current and Future**

"Many regulatory agencies expect to receive, and currently accept MIDD as part of dossier submissions"

### STATE OF THE ART

### Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations

Yaning Wang<sup>1</sup>\*, Hao Zhu<sup>1</sup>, Rajanikanth Madabushi<sup>1</sup>, Qi Liu<sup>1</sup>, Shiew-Mei Huang<sup>1</sup> and Issam Zineh<sup>1</sup>

Office of Clinical Pharmscology, Office of Translational Sciences, US Food and Drug Administration, Silver Spring, Maryland, USA. \*Correspondence: Yaning Wang (Yaning, Wang@Hda.hhn.gov)

Received 23 October. 2018; accepted 26 December, 2018. doi:10.1002/cpt.1363

CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 105 NUMBER 4 | APRIL 2019

### Future:

- MIDD pilot
- Mechanistic models
- Machine-learning models
- Real-world data/real-world evidence



Figure 1. Regulatory application of model information drug, development.



### Draft PhRMA MIÓD ICH paper(2019)

	No. 7 2018		
Ξ	Title: DRAFT ICH Reflection on Woodd-Informed-Drug		
ż	Development (MIDD/E		
3	1		
ŝ	Table of Contents 1		
5	1		
8	1 + Executive Summary.	.2	
	2 < Beckground -	.>	
Ξ	A -MED Dravkey Detailtien Visio and Registrary Applications - +	3	
٠	3 New CPVUU Renamisation and Randow Arrived - Acted - Action OVMUU		
	Ramaritadian	-9	
	§ – Need for Harmer Start Candolnes (or Acceptable Applications of 1877).		
2	() Nord by later hood Geldon coordinate Quality and Evolution 4.7		
а,	IB-Rock for Completionate Buildance at WED-Book Practice		
я,	3 - Propased COVID Divide lines. Alexi-Inducts. Objectives, and Outlanes	12	
5	A - Proceed-C+ MED Way Projects and Objectives	-3	
	8 - Encested Seller bro Sky Thereading CRINIDE Calculation		
÷.	C +Process/Optime to Harman state of Agency specify Guidelines on MDU+		
	2 - Phoned-Datase to Revisions to Custing Tapic Screets (DI-Sudshars, +	12	
	d Propawd Wark Plan	16	
	A Heed to an MDD Discourse Group -	-5	
2	E - Condusion	15	
2	6 Fgata	17	
à.	7. + Roterne tot	20	
×	1		

### **EFPIA** MIDD White paper(2016)

#### WHITE PAPER

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation The second second is second to be present to second the second second to be second to be second to be the second to be s

And (here) is a constraine to water game constraint in the process, we define our processing of the pro-ter shares in the constraint of the state of the process in the program of the process of the pro-ter shares in the process of the processing of the processing of the processing of the processing of the pro-perty of the processing of the pro-perty of the processing of the processing of the processing of the processing of the pro-ter of the processing of the pro-ter of the processing of the pro-ter of the processing of the pro-ter of the processing of the pro-ter of the processing of the processing of the processing of the processing of the pro-ter of the processing of the processing of the processing of the processing of the pro-ter of the processing of the processing of the processing of the processing of the pro-ter of the processing of the processing of the processing of the processing of the pro-ter of the processing of the processing of the processing of the processing of the pro-ter of the processing of the processing of the processing of the processing of the pro-ter of the processing of the pro-ter of the processing of the pro-ter of the processing of the pro-ter of the processing of the pro-ter of the processing of the pro-ter of the processing of the procesing of the proces

Altoration: MOM: Complex Addition and altor probability and a start of the start of

the state of the second s

## **Growing global interest in MIDD Standardisation**

PMDA – Population <u>PK/PD</u> 2019

1.1.1.1.1.1.1.1 141 INDEPARTURE OF THE OWNER 1.1. 160.00 L balyprendare 5-1. Characterial simulations when Art. Francis characteristic control and and a trick francis a develop a proved \$11.5. Fature on in described in the enclosis started must shall be 5-1-5 Prinster a style interation data at order of other and an area 21.1441-0414 111 Bloomspins and a straight last 225 Dependencies and the restriction of 33.0. Vallerer 24 Hole helding and dispersing both the data of the both of the both of the dispersion of the both 6.1.2. Displace of the ready who readed 24 Sleis millerere ArModel in third ar we recompared the particulation of the second state of the second state and the second tit tite a rid toke. · Bearing and you doe with a star 11.0444554445544 +2 Providing (where the state of the prime) 

Exposure Response 2020

contras las del comparison de las reservoirs de las de las model to de la trataria el las preside comparaçãos das asses. As de contra del traval assey presente en stratage, and the comparison, the transit chait respect. Processed in a class. Null Ry America & (8) 4 (ex. 5, 12) Gentering for hope and thereine day has of Deep i theate .1 Decigional ant objection 1) The second seco Malpinget
 Repairs drama
 Repairs drama and prices

Referant guidelings and departures

Charple of a figure present by exposure exposure makes a first schedule and the set of a strength of the set of the set

to make

2020 echnical Guideline on Model-Informed Drug Developme		
t. ruja		
frierskulter	· · · · · · · · · · · · · · · · · · ·	
l Han-Course		
II. Application of Modeling and Sanchroom in Dire	R Developments	
V Deer Swaren and Quality for Model Analyses	GAL MARKE	
Implementation of Mindelby and Simulation		-1
di Madhe nal caladia		
(II) Sine dation and application		9T
(III)-Birdy again.		N
(IV) Quality closed		
O Regulatory Considerations		
TI Keferanaa		18

NMPA -

**Population PK** 

2020

Technical Guidelines for Population Pharmacokinetic Study

Table of Contrast (

El Educer el solición estecio le realizador las cuances

differences and an even of the second s

(The Theorem 1 and not defend and advance because of the second sec

II. Reformation in the solution of the solution of

CONTRACT.

O Report application (projection) or other syndromer

DV: Nuty in clicker laters .

(if) Roberts I would and the

III (Deckler her blands)

Annealth I. Channeling Calified Channelsoffice Review, res. 109

MIDD

Discol man

THE RECEIPTION OF

(D) Contraction EVI Socializations.

(92) Hilton

#§ historiepite

Quality ratios 1

ini and

OF DESCRIPTION OF

(N) Male values

Designed have shown

T Dais Asserbax

Instruction store protection

PBP	K 2019
Buddee on the is promacounter p	porting of physickepically haved MMC modering 242 amulation
Talara et Cantorta	
established an enter any	
1. Legaritate	

2. hep-.

A. Brannin

Single
 Single
 Single

an. Wald pi 11 minute 11 minute 11 minute 11 de Thomas

Contraction of the second

na water 12 Double

D-Million

Thermost is

Appro da I

Selfaster e quittente bé equite belente est concerne te en trabai

Appendix a

TOLL + 27.8 CNU159/24/28

-10

EMA –

### FDA -**PBPK 2018**

THE REAL PROPERTY AND	
e on the reporting of physiologically haved connecter (PRPR) incidening 2x8 amutotest	Physiologically Based
Castoria	
a.em/ary	Pharmacokinetic
(++)	
	Analyses — Format and
Provide and and and an and an and an and an and	5. C
ng of MIRE magnifies) and chinebries	Content
e pil esalite e comi	Content
	Guidance for Industry
1	Guidance for industry
after A.	
datariani American I	
adarters and Marging with	
HOTEL	
ier d'exchemite annuire	
No. 1 Protocol and a second	
desides a produced screening of the response service screening of the	
and de explore a subjecte	
tinnin surpression and	
I Grand Carlon of the PREX planters	1.24. Dependent of the additional Research Research Evolution Deep Administration Control for Deep Evolution and Research (CDDR)
Contrast et anne	1-2 m ( 1812
in a set of the set of	Claim Hanacalay
a diversities and the participant of the rough seni. In	

### Extrapolation 2018 0 RUROPEAN MILDICINES AGENCY

#### Reflection paper on the use of extrapolation in the development of medicines for paediatrics

	Con Departure (Mercing Pers), People ing and Structure in ty, Premised deaths Werking Perty and Scientific Advise My	Ngeadwodt -
Charl Advated to Wolf.		215 (114 11 28)
		12 04 600 107 7
NACANA	and a second	18.0444-007
Second public contraination (and of consultation index data for commercial)		13 Detable- 20,7
		14 (Male) 2020
	n, ag ren Las Karlandels - Mersing Kota, Parle lag and Marsing Kota, Phanasachingto Weising Yeta and Sakarifi- King Kuty	Segura
-	A AN ADD THE MOST	7 August 2018
Text was an Advanced to 1900 Text was an Advanced to 2000		17 Detaber 2010
		27 October 2020
Rieva ce	Particular de la construir a participa de caracitario en la caracitario de la caracitaritario de la caracitaritario de la caracitaritarita	a, modelling and

MIDD Pilot
2018
odel-Informed Drug Development Pilot Program
the second second second
heleelin in bled tepice maren (ed in 1996, held), morie ing r

Mobile Educed Ding Processor, MEDU History and the line development and qualitation of exposite-based, building, and that bit include decived them and shelpsi data bini asara, niverila ta MDO uprasira. MDD uprasira ers with a classification of classification of the states and been been a classification of the personal devicement. How report the and will HERE approaches and hereinstated tild of ideor, between the table if by of regulators havons, and not taken done. there, the specific individual to the share on the individual to be

### What's New

Second A Thread which States I Deniet Colonal & Terrara Mar Viellay Science alter Tailage 18.8 Caretains, Moldicheast Dag bedge and all his Rockell, Per-MCD For Regard Postedly Adoption State

9



## **ICH MIDD Discussion Group**

LAST NAME	PARTY
Ahamadi	BIO
Peterson	BIO
Bose	CDSCO, India
Zhao	Bill and Melinda
	Gates Foundation
Karlsson	EC, Europe
Manolis	EC, Europe
Musuamba Tshinanu	EC, Europe
Frey	EFPIA
Lippert	EFPIA
Tegenge	FDA, United States
Wang	FDA, United States
Zineh	FDA, United States
	Health Canada,
Sarem	Canada
	Health Canada,
Zhang	Canada
Farkas	IGBA
Filipe	IGBA
Kawai	JPMA
Ueno	JPMA
	Ahamadi         Peterson         Bose         Zhao         Karlsson         Manolis         Musuamba Tshinanu         Frey         Lippert         Tegenge         Wang         Zineh         Sarem         Zhang         Farkas         Filipe         Kawai

FIRST NAME	LAST NAME	PARTY
		MFDS, Republic of
Ja-Young	Kim	Korea
Daisuke	Iwata	MHLW/PMDA, Japan
Yasuto	Otsubo	MHLW/PMDA, Japan
Jian	Li	NMPA, China
Ming	Zhou	NMPA, China
Erin	Greene	PhRMA
Scott	Marshall	PhRMA
Amit	Roy	PhRMA
Mohamad	Shebley	PhRMA
Omar	Almazroo	SFDA, Saudi Arabia
Chien-Lung	Tu	TFDA, Chinese Taipei
Observers		
Amanda	Roache	PhRMA ICH Supporter
Anne	Latrive	ICH Secretariat
Nadia	Myers Biggs	ICH Secretariat



## **Remit of ICH MIDD Discussion Group - 1 Year term**

- Finalize the scope of a general principles guideline for MIDD
- Position this proposal with respect to revision of ICH E4
- Develop a multi-year plan for integration of MIDD in existing ICH guidelines & consider potential new guidelines



## Impact of lack of harmonisation

- Missed opportunities to fully leverage MIDD
- An over reliance on traditional approaches to answering drug development & review questions
- Inefficient drug development strategies and study designs
- Unnecessary delay in the availability of new innovative medicines



# What is the biggest challenges to further implementation of MIDD ?

Choose all that apply

- A-Limited opportunity to apply MIDD in drug development
- B- The lack of Belief that MIDD can be useful in drug development
- C- The lack of common understanding of MIDD between technical and non-technical experts
- D- The lack of common standards & understanding of terminology
- E- Variable level of integration of MIDD into regulatory submissions



# What is the biggest challenges to further implementation of MIDD ?

- X A- Limited opportunity to apply MIDD in drug development
- **X** B- The lack of belief that MIDD can be useful in drug development
- ✓ C- The lack of common understanding of MIDD between technical and non-technical experts
- ✓ D- The lack of common standards & understanding of terminology
- ✓ E- Variable level of integration of MIDD into regulatory submissions



## **Summary & Next steps**

- Impact of Model Informed Drug Development
  - o Industry: Make drug development more efficient
  - Regulators: Enhance regulatory review
  - Patients: Reduce unnecessary exposure & provide earlier access to break through medicines
- ICH MIDD Discussion group is aligned on the need and value of a general principles guideline
- An updated ICH MIDD topic proposal is currently underdevelopment



# Questions?



### **Patient Focused Drug Development**

### Robyn Bent, RN, MS

Director, Patient-Focused Drug Development Program CDER, U.S. FDA

FDA and Health Canada Regional ICH Consultation – 14 May 2021



Background

Opportunities to incorporate patient experience data

Possible topics for future ICH Guideline development

Update on the status of the reflection paper and next steps




### Background PFDD Reflection Paper

identifies key areas where incorporation of the patient's perspective could improve the quality, relevance, safety and efficiency of drug development and inform regulatory decision making.

presents opportunities for development of new ICH guidelines to provide a globally harmonized approach to inclusion of the patient's perspective in a way that is methodologically sound and sustainable for both regulated industry and regulatory authorities.

### Background PFDD Reflection Paper





## Background

Patients are experts on what it is like to live with their condition

There is an opportunity to increase the quality of drug development programs through effective inclusion of patients' perspectives Methods for identifying, collecting, and analyzing what is meaningful to patients are not standard for harmonized

Patient advocacy and patient engagement is increasing and advancing



## Background

Regulators and drug sponsors need to employ methods and measures that:

- can be deployed in a timely and sustainable way
  - will be relevant to patients (and their caregivers)
  - reflects concepts that matter and measure changes that would be meaningful

ensure information collected can be used

• account for heterogeneity or subgroups.





What are patients' unmet needs that suggest potential drug targets?

What disease effects and treatment burdens matter most to patients?

What endpoint are most relevant to patients?

Incorporating patient experience data

FDA

ΣĪ

Methods and approaches to identify:

- Desirable treatment benefits
- Benefit-Risk tradeoffs



Methodological considerations for sponsor conduct of patient preference studies

Incorporating patient experience data

## Possible topics for future ICH Guideline development





## Possible guideline addressing what to measure in a clinical trial

Possible guideline addressing methods for elicitation or collection of assessments looking at patients' perspectives on alternative outcomes or other specified alternative attributes

### Updates and Next Steps

Public Consultation-

- Closed 07 March 2021
- Received over 300 comments from over 35 stakeholders
- Overall supportive of the effort moving forward
- Contain recommendations to be considered if new guidelines are developed

### Updates and Next Steps



Limited Examples of Related Ongoing Work

- U.S. FDA Patient-Focused Drug Development Guidance Series
  - <u>https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical</u>
- IMI PREFER project
  - https://www.imi-prefer.eu/

### Updates and Next Steps

Transparency



Reflection paper posted for comment

Any new guidelines will follow an engagement approach like that of ICH E6(R3)

## References



- ICH PFDD Reflection Paper
  - <u>https://admin.ich.org/sites/default/files/2020-</u>
     <u>12/ICH ReflectionPaper PFDD Endorsed-</u>
     <u>ForConsultation 2020 1118.pdf</u>



## **Questions?**

### **Robyn Bent, RN, MS** Director, Patient-Focused Drug Development Program CDER, U.S. FDA

Health Canada Santé Canada





# Open Q&A begins shortly – type your questions in the Q&A pod now.

Additional questions or comments? Email: <u>CDERSBIA@fda.hhs.gov</u> Health Canada Santé Canada





## Thank you for attending!

Additional information on ICH is available at www.ich.org

Additional information on CDER Small Business & Industry Assistance webinars and resources are available at

https://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ default.htm